Severe side effects and drug plasma concentrations in preterm infants treated with doxapram

Therapeutic Drug Monitoring

Volumn 21, Issue 5, 1999, Pages 547-552

  Barbé, Françoise ^a   Hansen, Catherine ^a   Badonnel, Yves ^a   Legagneur, Henryse ^a   Vert, Paul ^a   Boutroy, Marie Jeanne ^a  

^a Maternite Regionale Universitaire   (France)

Author keywords

Analysis; Doxapram; High performance liquid chromatography; Newborn; Toxicity

Indexed keywords

AHR 0914; AHR 5904; DOXAPRAM; DRUG METABOLITE; KETODOXAPRAM; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; APNEA; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NERVOUSNESS; NEWBORN; ORAL DRUG ADMINISTRATION; PREMATURITY; PRIORITY JOURNAL; SEIZURE; TACHYCARDIA; TECHNIQUE; TREMOR; VOMITING;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXAPRAM; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0032882692     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199910000-00011     Document Type: Article

References (15)

1. Barrington KJ, Finer NN, Torok-Both G, et al. Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. Pediatrics 1987;80:22-7.
2. Peliowski A, Finer NN, A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. J Pediatr 1990;116:648-53.
3. Bairam A, Boutroy MJ, Vert P. Un stimulant respiratoire, le doxapram, et ses applications en pédiatrie. Arch Fr Pediatr 1992;49: 469-74.
4. Bairam A, Blanchard PW, Mullahoo K, et al. Pharmacodynamic effects and pharmacokinetic profiles of keto-doxapram and doxapram in newborn lambs. Pediatr Res 1990;28:142-6.
5. Hayakawa F, Hakakawa S, Kuno K, et al. Doxapram in the treatment of idiopathic apnea of prematurity: desirable dosage and serum concentration. J Pediatr 1986;109:138-10.
6. Tay-Uyboco J, Kwiatkowski K, Cates D, et al. Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. Biol Neonate 1991;59:190-200.
7. Aranda JV, Beharry K, Rex J, et al. High performance liquid chromatographic microassay for simultaneous measurement of doxapram and its metabolites in premature newborn infants. J Liq Chromatogr 1988;11:2983-91.
8. Jamali F, Barringon KJ, Finer NN, et al. Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. Dev Pharmacol Ther 1988;11:253-7.
9. Boutroy MJ, Dalati M, Barbé F, et al. Doxapram per os: an alternative to IV infusion in treating apnea of prematurity? Pediatr Res 1994;35:82A.
10. Vert P, Boutroy MJ, Bairam A, Barbé F. Le doxapram dans les apnées du prématuré : mode d'action et résultats. In: Relier JP, ed. Progrès en Néanatologie. Bâle, France: Karger; 1996;16:79-84.
11. Kumita H, Mizuno S, Shinohara M, et al. Low-dose doxapram therapy in premature infants and its CSF and serum concentrations. Acta Paediatr Scand 1991;80:786-91.
12. Le Gatt DF, Beaudry MA, Bradley JM. Simultaneous determination of doxapram and 2-ketodoxapram in plasma of neonates by gas-chromatography. J Chromatogr 1986;378:478-81.
13. Robson RH, Prescott LF. Rapid gas-liquid chromatographic estimation of doxapram in plasma. J Chromatogr 1977;143:527-9.
14. Torok-Both GA, Coutts RT, Jamali F, et al. Sensitive nitrogen-phosphorus capillary gas chromatographic assay for Doxapram in premature infants. J Chromatogr 1985;344:372-7.
15. Nichol H, Vine J, Thomas J. Quantification of doxapram in blood, plasma and urine. J Chromatogr 1980;182:191-200.